China’s NMPA Addresses Common Period Risk Evaluation Report (PRER) Issues

China’s NMPA updates and address some common issues faced by the Marketing Authorization Holders to submit PRER report.
Pharmacovigilance in China

On 2017, China began the harmonization of their pharmacovigilance structure when they joined the ICH. GRP’s blog breaks down the structure of china reporting system and the requirements of a PMF.